Efficacy of Fractional Er:YAG Laser in Lupus Erythematosus Scars

Status Withdrawn

Clinical Trial Summary

Cutaneous Lupus erythematosus (CLE) is a chronic autoimmune connective tissue disease with a prevalence of 14.6 - 73.2/100,000, predominantly in women in mid adulthood. Cutaneous lesions occur in about 75-80% of patients with systemic lupus erythematodes.These lesions unfortunately and invariably lead to significant scarring and postinflammatory hypo- and hyperpigmentation. Several studies have reported that laser treatments in patients with CLE have a positive effect and safety. However, only few case reports exist about the effect of ablative lasers such as Carbon Dioxide (CO2) and Erbium-doped Yttrium Aluminum Garnet (Er:YAG) lasers in CLE scarring. Although no study shows a flare-up of CLE after laser treatment of the scars, many physicians are afraid of treating these often stigmatizing scars. Considering the huge psychological impact of facial scaring on quality of life, it is essential to explore and assess the value of already well-established treatment options for the management of scars also in patients with cutaneous lupus erythematodes. Hereby the study seeks the subjective and objective improvement of the CLE-scars after treatment with fractional Er:YAG laser compared to control (untreated) areas.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04707924
Study type	Interventional
Source	University Hospital Inselspital, Berne
Contact
Status	Withdrawn
Phase	N/A
Start date	June 1, 2021
Completion date	December 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02034344` - A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers	Phase 0
Terminated	`NCT01559155` - Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
Completed	`NCT01702740` - A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus	Phase 1
Withdrawn	`NCT00222183` - Cutaneous Lupus Erythematosus and Elidel	N/A
Recruiting	`NCT05879718` - A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.	Phase 2
Completed	`NCT01352988` - Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus	Phase 2
Enrolling by invitation	`NCT00420121` - European Society of Cutaneous Lupus Erythematosus (EUSCLE)	N/A
Completed	`NCT01845740` - Phase Ib Study of SC Milatuzumab in SLE	Phase 1
Completed	`NCT02927457` - Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects	Phase 1
Completed	`NCT02656082` - Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus	Phase 2
Terminated	`NCT02428309` - Autologous Polyclonal Tregs for Lupus	Phase 1
Completed	`NCT04493541` - A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus	Phase 1
Terminated	`NCT01407679` - Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus	Phase 2
Completed	`NCT01923415` - A Non-drug Study Profiling Cutaneous Lupus	Phase 0